HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dual VEGFR-2/PIM-1 kinase inhibition towards surmounting the resistance to antiangiogenic agents via hybrid pyridine and thienopyridine-based scaffolds: Design, synthesis and biological evaluation.

Abstract
Angiogenesis is a hallmark in cancer. Most antiangiogenic agents block the action of vascular endothelial growth factor (VEGF). In clinic, patients develop hypoxia-mediated resistance consistent with vascular responses to these agents. Recent studies underlying such resistance revealed hypoxia-inducible PIM-1 kinase upregulation which promotes cancer progression. PIM-1 kinase expression is thus viewed as a new resistance mechanism to antiangiogenic agents. Hence, combining PIM kinase inhibitors with anti-VEGF therapies provides synergistic antitumor response. Inspired by these facts, the current study aims at designing novel dual VEGFR-2/PIM-1 kinase inhibitors via molecular hybridization and repositioning of their pharmacophoric features. Moreover, enhancing the cytotoxic potential of the designed compounds was considered via incorporating moieties mimicking caspase 3/7 activators. Accordingly, series of novel pyridine and thieno[2,3-b]pyridine derivatives were synthesized and screened via MTT assay for cytotoxic activities against normal fibroblasts and four cancer cell lines (HepG-2, Caco-2, MCF-7 and PC-3). Compounds 3a, 9e, 10b and 10c exhibited anticancer activities at nanomolar IC50 with promising safety, activated caspase 3/7 and induced apoptosis as well as DNA fragmentation more than doxorubicin in the four cancer cell lines. Furthermore, they exerted promising dual VEGFR-2/PIM-1 kinase inhibition and significantly exhibited higher therapeutic potential to alter the expression levels of VEGF, p53 and cyclin D than doxorubicin. Interestingly, the most active anticancer compound 10b conferred the highest dual VEGFR-2/PIM-1 kinase inhibition. Finally, their in silico ligand efficiency metrics were acceptable.
AuthorsOla H Rizk, Mohamed Teleb, Marwa M Abu-Serie, Omaima G Shaaban
JournalBioorganic chemistry (Bioorg Chem) Vol. 92 Pg. 103189 (11 2019) ISSN: 1090-2120 [Electronic] United States
PMID31473473 (Publication Type: Journal Article)
CopyrightCopyright © 2019 Elsevier Inc. All rights reserved.
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyridines
  • Doxorubicin
  • Vascular Endothelial Growth Factor Receptor-2
  • Proto-Oncogene Proteins c-pim-1
  • Caspases, Effector
Topics
  • Angiogenesis Inhibitors (chemical synthesis, pharmacology)
  • Antineoplastic Agents (chemical synthesis, pharmacology)
  • Apoptosis (drug effects)
  • Caspases, Effector (metabolism)
  • Cell Line, Tumor
  • Doxorubicin (pharmacology)
  • Drug Resistance, Neoplasm (drug effects)
  • Drug Screening Assays, Antitumor
  • Humans
  • Molecular Structure
  • Protein Kinase Inhibitors (chemical synthesis, pharmacology)
  • Proto-Oncogene Proteins c-pim-1 (antagonists & inhibitors)
  • Pyridines (chemistry)
  • Structure-Activity Relationship
  • Vascular Endothelial Growth Factor Receptor-2 (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: